Targeting the PAX3-FOXO1 protein in a deadly childhood cancer
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma
This study is looking at a specific protein that helps a serious childhood cancer called alveolar rhabdomyosarcoma grow, with the hope of finding new ways to treat this cancer and help kids live healthier lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10221086 on NIH RePORTER |
What this research studies
This research focuses on understanding and targeting the PAX3-FOXO1 fusion protein, which plays a critical role in the development of alveolar rhabdomyosarcoma (ARMS), a severe form of childhood cancer. The project aims to identify the molecular vulnerabilities associated with this protein to develop new therapeutic strategies. By employing a combination of advanced biological techniques and data analysis, the research seeks to uncover the mechanisms that allow this protein to promote tumor growth. Ultimately, the goal is to create effective treatments that can improve survival rates for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with alveolar rhabdomyosarcoma, particularly those with the PAX3-FOXO1 fusion protein.
Not a fit: Patients with other types of rhabdomyosarcoma or those without the PAX3-FOXO1 fusion protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that significantly improve survival rates for children with PAX3-FOXO1-positive rhabdomyosarcoma.
How similar studies have performed: While the specific targeting of the PAX3-FOXO1 fusion protein is a novel approach, similar strategies targeting oncogenic proteins have shown promise in other cancers.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Linardic, Corinne Mary — Duke University
- Study coordinator: Linardic, Corinne Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.